» Articles » PMID: 36536448

VHL-recruiting PROTAC Attenuates Renal Fibrosis and Preserves Renal Function Via Simultaneous Degradation of Smad3 and Stabilization of HIF-2α

Overview
Journal Cell Biosci
Publisher Biomed Central
Specialty Biology
Date 2022 Dec 19
PMID 36536448
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Renal fibrosis is the pathological foundation of various chronic kidney diseases progressing to end stage renal failure. However, there are currently no nephroprotective drugs targeted to the fibrotic process in clinical practice. Proteolytic targeting chimeras (PROTACs), which reversibly degrade target proteins through the ubiquitin-proteasome pathway, is a novel therapeutic modality. Smad3 is a key pathogenic factor in fibrogenesis while HIF-2α exhibits prominent renal protective effects, which is the natural substrate of von Hippel-Lindau (VHL) E3 Ligase. We hypothesied the construction of VHL-recruiting, Smad3-targeting PROTAC might combine the effects of Smad3 degradation and HIF-2α stabilization, which not only improving the clinical efficacy of PROTAC but also avoiding its potential off-target effects, could greatly improve the possibility of its translation into clinical drugs.

Methods: By joining the Smad3-binding small molecule compound (SMC) to VHL-binding SMC with a linker, we designed and synthesized a Smad3-targeting, VHL-based PROTAC. The effects of this PROTAC on targeted proteins were verified both in vitro and in vivo. The toxicity and pharmacokinetic (PK) evaluations were conducted with both male and female mice. The renal protection effects and mechanism of PROTAC were evaluated in unilateral ureteral obstruction (UUO) and 5/6 subtotal nephrectomy (5/6Nx) mouse model.

Results: By optimizing the linker and the Smad3-binding SMC, we got a stable and high efficient PROTAC which simultaneously degraded Smad3 and stabilized HIF-2α both in vivo and in vitro. The acute toxicity evaluation showed a pretty large therapeutic window of the PROTAC. The prominent renal protection effects and its underlying mechanism including anti-fibrosis and anti-inflammatory, improving renal anemia and promoting kidney repair, had all been verified in UUO and 5/6Nx mouse model.

Conclusion: By accurate combination of PROTAC targeted protein and E3 ligase, we got a Smad3-targeting, VHL-recruting PROTAC which caused Smad3 degradation and HIF-2α stabilization effects simultaneously, and led to the strong renal function protection effects.

Citing Articles

Collagen formation, function and role in kidney disease.

De Gregorio V, Barua M, Lennon R Nat Rev Nephrol. 2024; 21(3):200-215.

PMID: 39548215 DOI: 10.1038/s41581-024-00902-5.


Renal tubular epithelial cell quality control mechanisms as therapeutic targets in renal fibrosis.

Bao Y, Shan Q, Lu K, Yang Q, Liang Y, Kuang H J Pharm Anal. 2024; 14(8):100933.

PMID: 39247486 PMC: 11377145. DOI: 10.1016/j.jpha.2024.01.001.


Targeted dephosphorylation of SMAD3 as an approach to impede TGF-β signaling.

Brewer A, Zhao J, Fasimoye R, Shpiro N, Macartney T, Wood N iScience. 2024; 27(8):110423.

PMID: 39104417 PMC: 11298613. DOI: 10.1016/j.isci.2024.110423.


Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.

Bouvier C, Lawrence R, Cavallo F, Xolalpa W, Jordan A, Hjerpe R Cells. 2024; 13(7.

PMID: 38607017 PMC: 11011670. DOI: 10.3390/cells13070578.


Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases.

Talukdar P, Chatterji U Signal Transduct Target Ther. 2023; 8(1):427.

PMID: 37953273 PMC: 10641101. DOI: 10.1038/s41392-023-01651-w.


References
1.
Wang X, Chaudhry M, Nie Y, Xie Z, Shapiro J, Liu J . A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy. J Vis Exp. 2017; (129). PMC: 5755318. DOI: 10.3791/55825. View

2.
Kapitsinou P, Sano H, Michael M, Kobayashi H, Davidoff O, Bian A . Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury. J Clin Invest. 2014; 124(6):2396-409. PMC: 4092875. DOI: 10.1172/JCI69073. View

3.
Xu M, Wang J, Xie J . Regulation of iron metabolism by hypoxia-inducible factors. Sheng Li Xue Bao. 2017; 69(5):598-610. View

4.
Haase V . Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol. 2006; 291(2):F271-81. PMC: 4232221. DOI: 10.1152/ajprenal.00071.2006. View

5.
Gerl K, Miquerol L, Todorov V, Hugo C, Adams R, Kurtz A . Inducible glomerular erythropoietin production in the adult kidney. Kidney Int. 2015; 88(6):1345-1355. DOI: 10.1038/ki.2015.274. View